• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Halo Neuroscience raises $13m in Series B

Halo Neuroscience raises $13m in Series B

January 31, 2018 By Fink Densford

Halo Neuroscience

Neurostimulation device maker Halo Neuroscience said today it raised $13 million in a Series B round of financing to support its Halo Sport neurostim headset designed to improve muscle memory acquisition from athletic training.

The funding round was led by TPG and joined by existing investors Lux Capital, JAZZ Venture Partners and XFund, the San Francisco-based company said.

“This round of funding is a testament to the proven science behind Halo, and to the enormous potential of the company in the areas of consumer and medical neuromodulation. Halo has pioneered a powerful new means of improving human performance, and we’re proud to stand behind its technology and leadership,” TPG’s Heath Lukatch, who joined Halo’s board, said in a prepared statement.

The company’s flagship device, the Halo Sport, is designed to deliver neurostimulation to the motor cortex in a 20 minute neuropriming session which Halo Neuroscience claims induces a temporary state of hyperplasticity that allows neural pathways from the motor cortex to the muscles to be optimized and strengthened.

“Halo is a leader in unlocking the potential in the brain’s capacity to learn, and stands as one of the most exciting new technologies I’ve seen in recent years. Currently used by elite athletes at the highest level of sport, we anticipate a wider audience to develop among those seeking to improve a broad range of human activity, from sports-specific skills to key cognitive functions,” board exec chair Peter Gotcher said in a prepared statement.

Halo Neuroscience said that the device is currently being used by organizations including the San Francisco Giants, the US Olympic Ski Team and US Special Operations Forces.

“What started in 2013 as a team of neuroscientists who believed in the power of neurostimulation has led to a global movement. We are proud to be the torchbearers in the space and are excited we now have the financial fuel to build and launch two new products that will further unlock human potential,” Halo co-founder Dr. Daniel Chao said in a press release.

Filed Under: Business/Financial News, Neuromodulation/Neurostimulation Tagged With: haloneuroscience

More recent news

  • Edwards earns FDA approval for first-of-its-kind size-adjustable pediatric heart valve
  • Leading medical device experts and MDO launch Medtech Innovation Board
  • Mitria Medical teams with Silicon Valley incubator for mitral repair device
  • Truvian links with Siemens Healthineers to advance benchtop blood testing
  • Medtronic snags breakthrough designation for below-the-knee drug-coated balloon

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy